Fierce Pharma April 3, 2024
Medicare drug price negotiations under the Inflation Reduction Act (IRA) are steadily progressing after drugmakers recently submitted their counteroffers to the government’s initial pricing proposals.
Now, the U.S. Department of Health and Human Services (HHS) has put forward its own responses to those counteroffers. In addition, the agency invited each company affected by the process to engage in “further discussions,” it said in a Tuesday press release.
The Centers for Medicare & Medicaid Services (CMS) is “proud to be negotiating in good faith with drug manufacturers to lower the prices of some of the most expensive drugs for people with Medicare,” CMS Administrator Chiquita Brooks-LaSure said in a statement.
The negotiation process officially kicked off on Feb. 1 with the...
Today's Sponsors
Today's Sponsor